Cleared Traditional

K082845 - INFINITI VISION SYSTEM WITH OZIL IP

K082845 is the FDA 510(k) clearance for INFINITI VISION SYSTEM WITH OZIL IP by Alcon Research, Ltd.. It is a Class 2 Ophthalmic device (product code HQC) cleared through the Traditional 510(k) pathway after a 139-day FDA review.

K082845 · Alcon Research, Ltd. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2009
Decision
139d
Days
Class 2
Risk

K082845 is an FDA 510(k) clearance for the INFINITI VISION SYSTEM WITH OZIL IP. Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Alcon Research, Ltd. (Fort Worth, US). The FDA issued a Cleared decision on February 12, 2009 after a review of 139 days - within the typical 510(k) review window.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Alcon Research, Ltd. devices

Submission Details

510(k) Number K082845 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 26, 2008
Decision Date February 12, 2009
Days to Decision 139 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
29d slower than avg
Panel avg: 110d · This submission: 139d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - HQC Unit, Phacofragmentation

All 81
Devices cleared under the same product code (HQC) and FDA review panel - the closest regulatory comparables to K082845.
xPORT Lens Fragmentation System
K191024 · Carl Zeiss Meditec Cataract Technology, Inc. · Aug 2019
CENTURION VISION SYSTEM
K121555 · Alcon Laboratories, Inc. · Dec 2012
STELLARIS PC VISION ENHANCEMENT SYSTEM
K101325 · Bausch & Lomb, Inc. · Aug 2010
BAUSCH & LOMB STELLARIS MICROSURGICAL SYSTEM
K082473 · Bausch & Lomb, Inc. · Jan 2009
BAUSCH & LOMB D4600A AIR EXCHANGE LINE PACK
K082132 · Bausch & Lomb, Inc. · Aug 2008
STERILS SINGLE-USE I/A HANDPIECES
K073023 · Bausch & Lomb, Inc. · Mar 2008